Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970762 | 0.86 | ATM (0.41) | TP53KCNA5CTSSCTSK | |
| SCHEMBL16979749 | 0.84 | FOLH1 (0.38) | MEN1NPC1HTTRAB9AKMT2A | |
| SCHEMBL16979737 | 0.83 | ALDH1A1 (0.40) | MEN1NPC1HTTRAB9AKMT2A | |
| SCHEMBL18472340 | 0.83 | HPGD (0.32) | — | |
| SCHEMBL18472382 | 0.82 | PAX8 (0.32) | PAX8USP2 | |
| SCHEMBL18472386 | 0.82 | CTSS (0.32) | PAX8CTSSCTSK | |
| SCHEMBL18472398 | 0.78 | IDO1 (0.33) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL18472390 | 0.78 | — | — | |
| SCHEMBL19730324 | 0.78 | IDO1 (0.33) | MEN1NPC1HTTRAB9AKMT2A | |
| SCHEMBL18472385 | 0.78 | IDO1 (0.33) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9861599-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | QUADRIGA BIOSCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9394237-B2 | β-substituted β-amino acids and analogs as chemotherapeutic agents | QUADRIGA BIOSCIENCES, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | QUADRIGA BIOSCIENCES, INC. | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218086-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | HCRTR1 3057/4885HCRTR2 2561/4885MEN1 3292/4885 |
| US-20160289172-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | HCRTR1 3057/4885HCRTR2 2561/4885MEN1 3292/4885 |
| US-20160346240-A1 | METHODS OF CHEMOTHERAPY USING CHEMOTHERAPEUTIC AGENTS BASED ON BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS | BCAT1, CDC25C, BCAT2 | HCRTR1 3690/4885HCRTR2 4262/4885MEN1 3730/4885 |
| US-20160296484-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | HCRTR1 3057/4885HCRTR2 2561/4885MEN1 3292/4885 |
| US-10034847-B2 | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | SLC7A1, SLC3A2, SLC1A5 | HCRTR1 3057/4885HCRTR2 2561/4885MEN1 3292/4885 |
| US-20160185710-A1 | BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS | SLC7A1, SLC3A2, SLC1A5 | HCRTR1 3057/4885HCRTR2 2561/4885MEN1 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.